Abstracts tagged "Cohort Study"

Abstract Number: 1510 • ACR Convergence 2024
Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Nidia Meras⁸, Cintia Otaduy⁹, Elisa Novatti¹⁰, Valeria Arturi¹¹, Erika S. Palacios Santillan⁷, Boris Kisluk¹², Luciana González Lucero¹³, Eduardo Kerzberg¹⁴, Nicolás Pérez¹⁵, Cecilia Pisoni¹⁶, Paola Pirruccio¹⁷, María E. Crespo¹⁸, Ana Carolina Montandon¹⁹, Andrese A. Gasparin²⁰, Angela Duarte²¹, Laissa C. Alves Alvino²², Eloisa Bonfa²³, Emily Figuereido Neves²⁴, Lucas Victoria De Oliveira Martins²⁵, Iris Guerra²⁶, Milena Mimica Davet²⁷, Lizeth De La Hoz Rueda²⁸, Andrés Cadena Bonfanti²⁸, Roberth Rivera²⁹, Paola Coral Alvarado³⁰, John Fredy Jaramillo³¹, José Martínez³², Mario Moreno³³, Reyna E. Sánchez Briones³⁴, Mario Pérez Cristóbal³⁵, Eduardo Martin Nares³⁶, Yaneli Juárez-Vicuña³⁷, Yelitza González Bello³⁸, Octavio González³⁹, Leonardo R. Aguilar Rivera⁴⁰, Margarita Duarte⁴¹, Patricia Langjarth⁴², Wilkerson Pérez Medina⁴¹, Armando Calvo⁴³, Teresandris Polanco⁴⁴, Carina Pizzarossa⁴⁵, Gonzalo Silveira⁴⁶, Cristina Reategui⁴⁷, Graciela Alarcon⁴⁸, Urbano Sbarigia⁴⁹, Federico Zazzetti⁵⁰, Ashley Orillion⁵¹, Guillermo Pons-Estel⁵² and Bernardo Pons-Estel⁵², ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Córdoba, Córdoba, Spain, ⁹Hospital Córdoba, Cordoba, Spain, ¹⁰Hospital Privado Universitario de Córdoba, Córdoba, Spain, ¹¹Hospital HIGA San Martín, La Plata, Argentina, ¹²Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ¹³Hospital Padilla, Tucumán, Argentina, ¹⁴Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹⁵Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁶CEMIC, Buenos Aires, Argentina, ¹⁷Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, ¹⁸Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ²⁰Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²¹Universidad Federal de Pernambuco, Pernambuco, Brazil, ²²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁴Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ²⁸Universidad Simon Bolivar, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³⁷Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, CDMX, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, Mexico, ⁴⁰Servicio de Reumatología (CEAR). Hospital Universitario "Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico, ⁴¹Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Cayetano Heredia, San Martin de Porres, Peru, ⁴⁴Hospital Docente Padre Billini, Santo Domingo, Dominica, ⁴⁵Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁶Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁷Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁸The University of Alabama at Birmingham, Birmingham, AL, ⁴⁹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵⁰Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵¹Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: To evaluate health-related quality of life (HRQoL) in patients with active lupus nephritis (LN) at baseline and 12 months after treatment in relationship to…
Abstract Number: 2041 • ACR Convergence 2024
Global Prevalence and Clinical Outcomes of Cogan Syndrome
Anna-Kay Palmer¹ and Irene Tan², ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Cogan syndrome (CS) is an extremely rare autoimmune systemic vasculitis characterized by intraocular inflammation and vestibulo-auditory dysfunction. The global prevalence of this disease is…
Abstract Number: 2268 • ACR Convergence 2024
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Claire Bombardier⁵ and Pooneh Seyed-Akhavan⁶, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Sinai Health System, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) who fail conventional synthetic treatment with disease modifying anti-rheumatic drugs (csDMARDs) are eligible for biological DMARDs (bDMARDs) or targeted…
Abstract Number: 2636 • ACR Convergence 2024
Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Stephen Pennington¹, Ruoyi Zhou², Jonathan Brady², Bruna Wundervald², Andrew Parnell³, Ciarán Duffy², Robert Perryman², James Waddington⁴, Neil McHugh⁵, Deepak Jadon⁶, David Simon⁷, Filippo Fagni⁸, Georg Schett⁹, Fraser Morton¹⁰, Aurelie Najm¹⁰, Stefan Siebert¹¹, Laura Coates¹² and Oliver FitzGerald¹³, ¹UCD, Dublin, Dublin, Ireland, ²Atturos, DUBLIN, Dublin, Ireland, ³NUIM, Maynooth, Ireland, ⁴Agilent, Manchester, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶Cambridge University, Cambridge, United Kingdom, ⁷Charité - Universittsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹³UCD, Dublin 6, Dublin, Ireland
Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
Abstract Number: 0249 • ACR Convergence 2024
Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study
Christos Koutsianas¹, Anastasia Apanomeritaki², Evgenia Mavrea¹, Niki-Violeta Dimopoulou¹, Maria Nitsa¹, CHRISTINA TSALAPAKI¹, Iro-Ioanna Giannakopoulou² and Dimitrios Vassilopoulos¹, ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ²Rheumatology Clinic, General Hospital Asklepieio Voulas, Voula, Attiki, Greece
Background/Purpose: Patients with rheumatic diseases (RD) are at increased risk for herpes zoster (HZ) due to disease -related aberrant immune response, comorbid conditions and anti-rheumatic…
Abstract Number: 0520 • ACR Convergence 2024
Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
Yoichi Nakayama¹, Daijiro Kabata², Wataru Yamamoto³, Hidehiko Makino⁴, Koji Nagai⁴, Naofumi Yoshida⁵, Yonsu Son⁵, Masaki Katayama⁶, Hirotaka Yamada⁷, Keisuke Nishimura⁷, Ryota Hara⁸, Ryu Watanabe⁹, Yuki Etani¹⁰, Kosuke Ebina¹¹, Hideo Onizawa¹², Takayuki Fujii¹³, Akira Onishi¹⁴, Kosaku Murakami¹⁵, Koichi Murata¹², Masao Tanaka¹⁴, Shuichi Matsuda¹², Akio Morinobu¹⁶, Ayumi Shintani² and Motomu Hashimoto⁹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Okayama, Japan, ⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁵First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan, ⁶Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, ⁸Department of Orthopaedic Surgery, Nara Medical University, Nara, Nara, Japan, ⁹Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ¹⁰Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹¹Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ¹³Kyoto University, Kyoto, Japan, ¹⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: A delay in initiating disease-modifying antirheumatic drugs (DMARDs) has been linked to poor outcomes in patients with rheumatoid arthritis (RA). Several studies have implicated…
Abstract Number: 0983 • ACR Convergence 2024
Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey
Aleksander Lenert¹, Mary E. Charlton¹, Jacob J. Oleson¹, Robyn Domsic² and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: General well-being, an individual’s subjective assessment of their life overall, may be impacted by arthritis. It is unclear if adults with arthritis have lower…
Abstract Number: 1328 • ACR Convergence 2024
Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study
Roslin Jose George¹, Noah Frechette¹, Iqra Javed¹, Bradly Kimbrough², Sara Achenbach³, Elena Joerns¹, Vanessa Kronzer¹, John Davis¹, Cynthia Crowson¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Carpal tunnel syndrome (CTS) is a common complication of rheumatoid arthritis (RA). However, the occurrence of CTS before RA and the effect of RA…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 2051 • ACR Convergence 2024
Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience
Guy Katz¹, Zachary Wallace², Grace McMahon¹, Isha Jha¹, Ana Fernandes¹, Bohang Jiang¹, Yuqing Zhang³, Hyon K. Choi⁴, Cory Perugino¹ and John Stone⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Rituximab (RTX) is often used to treat IgG4-related disease (IgG4-RD), but real-world data on clinical outcomes remain limited. Defining time to relapse and predictors…
Abstract Number: 2311 • ACR Convergence 2024
Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans
Natalie Anumolu¹, Ann Rosenthal¹, Katherine Sherman² and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee
Background/Purpose: CPPD has been shown to complicate other types of inflammatory arthritis such as rheumatoid arthritis. However, only a few studies have investigated the correlation…
Abstract Number: 2684 • ACR Convergence 2024
Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease
Ruhani Desai¹, Filemon Tan², Minghua Wu³, Jefferey Browning⁴, Samuel Theodore³, Meng Zhang³, Brian Skaug³, Maureen Mayes³ and Shervin Assassi³, ¹UTHealth Houston Division of Rheumatology, DeLand, FL, ²University of Texas at Houston McGovern Medical School, Houston, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Boston Univeristy, Boston, MA
Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
Abstract Number: 0252 • ACR Convergence 2024
Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Aurélien Chepy¹, Michaël Genin², Louis Terriou³, Cécile Chenivesse⁴, Delphine Staumont-Sallé⁵, Hélène Zéphir⁶, Peggy philippe⁷, Guillaume Lefevre⁸, Sarah Stabler⁹, Eric HACHULLA³, David Launay¹⁰ and Vincent Sobanski³, ¹Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, ²Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, F-59000, France., Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille, France, ⁴Centre de Référence Constitutif des Maladies Pulmonaires Rares, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille 59000, France., Lille, France, ⁵Service de dermatologie CHU Lille Université de Lille Lille France., Lille, France, ⁶Department of Neurology, CRC-SEP, CHU of Lille, Lille, France., Lille, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France., Lille, France, ⁸CHU Lille, Institut d’Immunologie, Lille, France., Lille, France, ⁹CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France; Univ. Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France., Lille, France, ¹⁰CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., Lille Cedex, France
Background/Purpose: Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells,…
Abstract Number: 0566 • ACR Convergence 2024
How Early Is Early? Unveiling Time to Diagnosis Since Symptom Onset and Its Determinants in Patients Suspected of Early Axial Spondyloarthritis: Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy Marques¹, Desiree van der Heijde², Liese de Bruin³, Miranda van Lunteren⁴, Robert Landewé⁵, Karen Minde Fagerli⁶, Maikel Van Oosterhout⁷, Floris van Gaalen⁸ and Sofia Ramiro⁹, ¹Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, the Netherlands, Gouda, Netherlands, ⁸LUMC, Leiden, Zuid-Holland, Netherlands, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Patients with chronic back pain (CBP) of less than two-years (2y) duration suspected of axial spondyloarthritis (axSpA) referred to the rheumatologist can be reliably…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].